Summit Therapeutics (SMMT) Interest Expenses (2017 - 2026)

Summit Therapeutics (SMMT) has reported Interest Expenses for 10 consecutive years, with $71000.0 the latest figure, recorded in Q2 2026.

• Quarterly Interest Expenses changed N/A year-over-year to $71000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $71000.0 (changed N/A YoY) and the FY2025 annual result came in at $3.7 million, down 99.78% from the prior year.
• Interest Expenses grew to $71000.0 in Q2 2026 per SMMT's latest filing, from $4000.0 in the prior quarter.
• Over the last five years, Interest Expenses for SMMT reached as high as $8.3 million in Q1 2023 and fell as low as $4000.0 in Q1 2026.
• A 5-year average of $2.5 million and a median of $2.7 million in 2023 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2023 — Interest Expenses soared 2703.7% — and 2025, when it slumped 98.94%.
• Year by year, Interest Expenses stood at $692000.0 in 2022, then soared by 324.71% to $2.9 million in 2023, then soared by 148.55% to $7.3 million in 2024, then tumbled by 99.55% to $33000.0 in 2025, then jumped by 115.15% to $71000.0 in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $71000.0, $4000.0, and $33000.0 for Q2 2026, Q1 2026, and Q1 2025 respectively.